S1126 Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) in Virally Suppressed Chronic Hepatitis B (CHB) Patients With Hepatic Impairment: Week 48 Results From a Phase 2 Open Label Study

Authors :: John F. Flaherty
Huy N. Trinh
Wan-Long Chuang
Magdy Elkhashab
Aric J. Hui
Jeong Heo
Tak Yin Owen Tsang
Ho S. Bae
Matthew Guion
Belinda Jump
Pietro Andreone
Vithika Suri
Shuyuan Mo
Anuj Gaggar
Susanna K. Tan
Harry L.A. Janssen
Young-Suk Lim
Source :: American Journal of Gastroenterology. 115:S566-S567
Publication Year :: 2020
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2020.

Subjects :: medicine.medical_specialty
Hepatology
Chronic hepatitis
Open label study
business.industry
Internal medicine
Hepatic impairment
Gastroenterology
medicine
business
Tenofovir alafenamide

Full Text Access

Tools